This was the stock's second consecutive day of losses.

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to ...

Lecanemab was approved in the U.S. in 2023 as the world's first drug to slow the cognitive decline associated with Alzheimer's. The treatment also has received approval in Japan, China, Europe and ...